Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Henry Li
Observed names:
Henry Qi-xiang Li,
Henry Qixiang Li,
Henry Qi‐Xang Li,
henry li
Institution:
Institut Curie
Observed institutions:
Peking University,
South Nassau Communities Hospital,
Indiana University Bloomington,
OceanX Technology (China),
Crown Bioscience (China),
State Key Laboratory of Natural and Biomimetic Drugs,
OceanX,
Keymed Biosciences Inc. (China),
Columbia University,
Institut Curie
show all 10
ORCID:
0000-0002-4673-1234
Observed ORCID:
0000-0002-4673-1234
OpenAlex ID:
A5101797368
In Vitro Susceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
2014
·
Henry Li
, Mark Estabrook
, et al.
·
Antimicrobial Agents and Chemotherapy
·
137
Cellular Motor Protein KIF-4 Associates with Retroviral Gag
1999
·
Yao Tang
, Ulrike Winkler
, et al.
·
Journal of Virology
·
111
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
2021
·
Johannes Brägelmann
, Carina Lorenz
, et al.
·
Nature Communications
·
85
PDF
Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model
2015
·
Jiahua Jiang
, Daisy Dandan Wang
, et al.
·
Oncotarget
·
43
PDF
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
2018
·
Joseph M. Gozgit
, Tzu-Hsiu Chen
, et al.
·
Oncotarget
·
24
PDF
Abstract 4059: Vaccination causes a clear subtype shifting of tumor infiltrate Treg in mouse breast cancer homografts
2018
·
Xiaoyu AN
, Davy Xuesong Ouyang
, et al.
·
Cancer Research
·
14
Translational and Clinical Relevance of PDX‐Derived Organoid Models in Oncology Drug Discovery and Development
2022
·
Rajendra Kumari
, Xiaoxi Xu
, et al.
·
Current Protocols
·
13
A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies
2026
·
Philippe De La Rochere
, Laure Loumagne
, et al.
·
Frontiers in Immunology
·
7
PDF
GLP‐compliant assay validation studies: considerations for implementation of regulations and audit of studies
2006
·
Henry Li
, Garreth Sharp
, et al.
·
The Quality Assurance Journal
·
5
323 Immunogenic syngeneic model MC38-OVA for the preclinical evaluation of immune evasion and checkpoint blockade
2021
·
Jessie Wang
, Kaixia Lian
, et al.
·
Journal for ImmunoTherapy of Cancer
·
4
PDF
A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009,a Novel Bsab Dual Targeting PD-1 x CD47,in Patients with EBV+ Non-Hodgkin Lymphoma (NHL)
2024
·
Lin Gui
, Keshu Zhou
, et al.
·
Blood
·
3
245 Human TLR8 knock-in mice potentiate immunotherapy responses of MC38 syngeneic tumors
2020
·
Shanshan Qi
, Hongjuan Zhang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma
2018
·
Joseph Kelleher
, Laurent Audoly
, et al.
·
Blood
·
3
Abstract 3581: Rapid conversion to resistance, of a colon PDX with ret-fusion, by ponatinib treatment could potentially be attributed to the introduction of the gate keeper mutation V804M
2015
·
Mengmeng Yang
, Jie Cai
, et al.
·
Cancer Research
·
3
Establishing a GLP compliance program for non‐toxicology safety studies
2004
·
Henry Li
, Susan Hawlk
, et al.
·
The Quality Assurance Journal
·
3
PDF
A phase 1b study investigating the safety, tolerability and preliminary efficacy of HX009 in post-immune checkpoint inhibitor (CPI) therapy advanced melanoma patients.
2025
·
Lili Mao
, Yu Chen
, et al.
·
Journal of Clinical Oncology
·
2
Abstract B068: The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research
2019
·
Xiaoxi Xu
, Limei Shang
, et al.
·
Molecular Cancer Therapeutics
·
2
Abstract A010: Development of OVA-expressing immunogenic syngeneic mouse tumor models: CT26-OVA and B16-OVA
2019
·
Ying Jin
, Phillip Shuzong Wang
, et al.
·
Molecular Cancer Therapeutics
·
2
Abstract LB-272: KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition
2019
·
Joseph F. Kelleher
, Veronica Campbell
, et al.
·
Cancer Research
·
2
Abstract 1369: In vitro and in vivo antitumor activity of TH3424: Preclinical rationale for a highly selective AKR1C3 prodrug for treating hepatocellular carcinomas
2016
·
Jianxin Duan
, Zhong Wang
, et al.
·
Cancer Research
·
2
Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts
2015
·
Ran Wu
, Sheng Guo
, et al.
·
Blood
·
2
196 Tumor-associated SIRPα expression evaluation in melanoma PDX models via IHC for potential ICI-predictive applications
2023
·
Xiaolong Tu
, Wenjuan Zhou
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 2980: HX009, a first-in-class PD1xCD47 BsAb, demonstrated anti-AML activity in PDX models
2023
·
Xiaoyu An
, Jinping Liu
, et al.
·
Cancer Research
·
1
Abstract P003: In vitro and in vivo characterization of CCR8 humanized mouse model (HuGEMM™)
2021
·
Daniel He
, Henry Li
·
Molecular Cancer Therapeutics
·
1
Abstract 502: In vitro characterization of antibodies targeting the SIRPα-CD47 phagocytosis checkpoint using tumor-associated macrophages from HuGEMM™ mice
2021
·
Xuefei Yan
, Hongjuan Zhang
, et al.
·
Cancer Research
·
1
Show more works
View as search
Works count:
97
Citation count:
482
H-index:
7
I10-index:
7
Year
Topic
Type